Skip to main content

Boehringer Ingelheim selects Certaras D360

Certara, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, has announced that pharmaceutical company Boehringer Ingelheim has chosen D360 as its global drug discovery platform. Certara’s D360 is an integrated solution for the query, analysis and visualisation of drug discovery and development data that will enable Boehringer Ingelheim to share that data across global working groups that can include external collaborators.

Boehringer Ingelheim plans to install the global data mining tool at three of its sites, located in Ridgefield, CT; Biberach, Germany; and Vienna, Austria. All of the sites are currently using different data sources, mining tools, and workflows for analysing information.


Media Partners